Cutler Group’s Provention Bio, Inc. Common Stock PRVB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-1,615
| Closed | -$38K | – | 4441 |
|
|
2023
Q1 | $38K | Sell |
1,615
-7,354
| -82% | -$92.3K | ﹤0.01% | 1522 |
|
|
2022
Q4 | $94K | Sell |
8,969
-4,221
| -32% | -$34.1K | 0.01% | 1194 |
|
|
2022
Q3 | $59K | Hold |
13,190
| – | – | ﹤0.01% | 1780 |
|
|
2022
Q2 | $52K | Buy |
13,190
+800
| +6% | +$3.79K | ﹤0.01% | 1930 |
|
|
2022
Q1 | $90K | Sell |
12,390
-200
| -2% | -$1.2K | ﹤0.01% | 1780 |
|
|
2021
Q4 | $70K | Hold |
12,590
| – | – | ﹤0.01% | 2139 |
|
|
2021
Q3 | $80K | Buy |
12,590
+8,200
| +187% | +$52.7K | ﹤0.01% | 2115 |
|
|
2021
Q2 | $37K | Buy |
4,390
+200
| +5% | +$1.61K | ﹤0.01% | 2756 |
|
|
2021
Q1 | $43K | Buy |
4,190
+2,690
| +179% | +$37.9K | ﹤0.01% | 2528 |
|
|
2020
Q4 | $25K | Buy |
1,500
+1,100
| +275% | +$16.5K | ﹤0.01% | 2524 |
|
|
2020
Q3 | $5K | Sell |
400
-500
| -56% | -$6.32K | ﹤0.01% | 3572 |
|
|
2020
Q2 | $12K | Sell |
900
-400
| -31% | -$5.05K | ﹤0.01% | 2782 |
|
|
2020
Q1 | $11K | Buy |
+1,300
| New | +$16.8K | ﹤0.01% | 2690 |
|
|
2019
Q4 | – | Sell |
-3,800
| Closed | -$33.9K | – | 4811 |
|
|
2019
Q3 | $25K | Buy |
3,800
+3,400
| +850% | +$34.4K | ﹤0.01% | 2040 |
|
|
2019
Q2 | $4K | Buy |
+400
| New | +$2.18K | ﹤0.01% | 3292 |
|
Other funds holding PRVB
Cutler Group's PRVB Position: Q2 2023 in Review
Cutler Group sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 1,615 shares — an estimated $38K sold.
Cutler Group first reported a position in PRVB in Q2 2019 and held it in 15 quarters. The position peaked at $94K in Q4 2022. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.
- Cutler Group reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Cutler Group sold 1,615 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $38K.
- Cutler Group first reported a position in Provention Bio, Inc. Common Stock in Q2 2019 and held it in 15 quarters.
- Cutler Group's Provention Bio, Inc. Common Stock position peaked at $94K in Q4 2022.
- 1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.
Based on Cutler Group's 13F filing for Q2 2023, filed 18 Jul 2023.